{"id":"pd-1inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Colitis"}]},"_chembl":{"chemblId":"CHEMBL1474985","moleculeType":"Small molecule","molecularWeight":"476.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 (programmed death receptor 1) is an immune checkpoint that normally suppresses T cell activity to prevent autoimmunity. Tumors exploit this pathway by expressing PD-L1/PD-L2 ligands to evade immune attack. PD-1 inhibitors restore anti-tumor T cell function by blocking this inhibitory signal, enabling the immune system to mount an effective response against cancer cells.","oneSentence":"A PD-1 inhibitor blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:58.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors and hematologic malignancies (specific indications not publicly detailed for this investigational agent)"}]},"trialDetails":[{"nctId":"NCT07328841","phase":"PHASE3","title":"Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-18","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":456},{"nctId":"NCT06159621","phase":"PHASE1","title":"CD40 Agonist and PD-1 Inhibitor in HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-07-02","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT07090707","phase":"PHASE2","title":"PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-01","conditions":"HNSCC, PD-1, Radiotherapy","enrollment":50},{"nctId":"NCT06417892","phase":"","title":"Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-04-15","conditions":"Gastric Cancer","enrollment":60},{"nctId":"NCT06250894","phase":"PHASE2","title":"Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-03-30","conditions":"PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer","enrollment":32},{"nctId":"NCT06173986","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-01-10","conditions":"Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer","enrollment":50},{"nctId":"NCT05980715","phase":"PHASE3","title":"PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-01-01","conditions":"HNSCC, Radiotherapy, PD-1","enrollment":324},{"nctId":"NCT03679767","phase":"PHASE2","title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2019-01-09","conditions":"Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer","enrollment":121},{"nctId":"NCT04542369","phase":"PHASE2","title":"Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-05-01","conditions":"Small-cell Lung Cancer","enrollment":15},{"nctId":"NCT05218629","phase":"PHASE2","title":"Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Qingdao Central Hospital","startDate":"2022-01-01","conditions":"Overall Survival","enrollment":20},{"nctId":"NCT05675462","phase":"PHASE1","title":"Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-03-01","conditions":"Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT05669092","phase":"PHASE3","title":"A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-11-01","conditions":"Toripalimab, Radiation","enrollment":174},{"nctId":"NCT05435768","phase":"","title":"PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2022-08-16","conditions":"Metastatic Solid Tumor","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immunotherapy","PD-1 antibody"],"phase":"phase_3","status":"active","brandName":"PD-1inhibitor","genericName":"PD-1inhibitor","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A PD-1 inhibitor is a type of small molecule that targets the PD-1 protein to modulate the immune system. It has been studied in various clinical trials, including those for metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic pancreatic cancer.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}